Can CML Progress to Multiple Myeloma?
No, chronic myeloid leukemia (CML) does not progress to multiple myeloma (MM)—these are two entirely distinct hematologic malignancies with different cell origins, molecular drivers, and natural histories. 1, 2, 3
Why These Are Separate Diseases
CML arises from an abnormal pluripotent hematopoietic stem cell carrying the Philadelphia chromosome [t(9;22)] and BCR-ABL1 fusion gene, which drives uncontrolled myeloid proliferation 1, 2, 4. Multiple myeloma originates from clonal plasma cells (terminally differentiated B lymphocytes) that produce monoclonal immunoglobulin (M-protein) and cause bone marrow infiltration, lytic bone lesions, and end-organ damage 5, 6, 7.
CML progresses through its own disease phases—from chronic phase to accelerated phase to blast phase—but this represents clonal evolution of the same BCR-ABL1-positive myeloid clone, not transformation into a plasma cell disorder 1, 8, 9, 3. Blast phase CML can be myeloid or lymphoid in phenotype, but it is never a plasma cell/myeloma transformation 9, 3.
Rare Simultaneous Occurrence
The simultaneous occurrence of CML and MM in the same patient is extraordinarily rare—only eight cases were documented in the literature as of 2009, with a few additional case reports since 10, 11, 12, 13. These represent two independent malignancies arising in the same individual, not progression of one disease into the other 10, 11, 13.
Key Features of Documented Concurrent Cases
- Both diseases are diagnosed by their own distinct criteria: CML requires BCR-ABL1 positivity and myeloproliferative features, while MM requires ≥10% clonal plasma cells, M-protein, and CRAB criteria (hypercalcemia, renal insufficiency, anemia, bone lesions) 1, 6, 2, 7.
- Fluorescence in situ hybridization (FISH) studies in reported cases showed BCR-ABL1 fusion signals in myeloid cells but not in plasma cells, confirming these are separate clonal populations 13.
- Each disease requires its own specific treatment: tyrosine kinase inhibitors (TKIs) for CML and proteasome inhibitor/immunomodulatory drug-based regimens for MM 10, 11, 12, 14.
Clinical Pitfalls to Avoid
Do not assume that cytopenias, bone lesions, or elevated protein in a CML patient represent disease progression—these findings should prompt evaluation for a second malignancy, including MM 5, 6, 7, 15. Obtain serum protein electrophoresis with immunofixation, serum free light chains, and bone marrow biopsy with CD138 staining if MM is suspected 6, 7, 15.
Do not delay appropriate workup when clinical features do not fit typical CML progression patterns—such as new hypercalcemia, renal dysfunction disproportionate to disease burden, or lytic bone lesions in a patient with well-controlled CML 6, 7, 15.
Do not confuse the rare synchronous presentation of two diseases with true disease transformation—the molecular and cellular origins remain distinct, and treatment strategies must address both malignancies independently 10, 11, 12, 13.